<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962401</url>
  </required_header>
  <id_info>
    <org_study_id>RemodelWM3</org_study_id>
    <nct_id>NCT02962401</nct_id>
  </id_info>
  <brief_title>Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia</brief_title>
  <acronym>RemodelWM3</acronym>
  <official_title>An Open Label Non-randomized Phase II Study Exploring &quot;Chemo-free &quot; Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective national multicenter open label phase II Remodel WM3 trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label non-randomized Phase II Study exploring chemo-free treatment association with
      Idelalisib and Obinutuzumab in Patient with relapsed refractory Waldenstrom's
      Macroglobulinemia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2017</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>8 years</time_frame>
    <description>From date of registration until the date of first documented progression or date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rates (ORR)</measure>
    <time_frame>Month 8</time_frame>
    <description>treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (RD)</measure>
    <time_frame>7 years and 4 months</time_frame>
    <description>from end of induction to the date of progression, relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>through study completion, an average of 8 years</time_frame>
    <description>time from start of induction to stable disease, progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>through study completion, an average of 8 years</time_frame>
    <description>time from start of induction day 1 cycle 1 to time of the next treatment for progression or relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of Idelalisib and Obinutuzumab
Cycle 1 :
Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15
Cycle 2 - 6 :
Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1
Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15
Cycle 2 - 6 :
Obinutuzumab 1000mg I.V.day 1</description>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <other_name>GA101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>6 cycles every 28 days
Cycle 1 :
Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment</description>
    <arm_group_label>Idelalisib and Obinutuzumab</arm_group_label>
    <other_name>Zydelig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Confirmed CD20 positive WM, according to the recommendations of the 2nd Workshop on
             WM.

          -  Presence of at least one criterion for initiation of therapy, according to the 2nd
             Workshop on WM.

          -  Recurrent fever, night sweats, weight loss, fatigue

          -  Hyperviscosity

          -  Lympadenopathy which is either symptomatic or bulky more or equal to 5cm in maximum
             diameter

          -  Symptomatic hepatomegaly and/or splenomegaly

          -  Symptomatic organomegaly and/or organ or tissue infiltration

          -  Peripheral neuropathy due to WM

          -  Symptomatic cryoglobulinemia

          -  Cold agglutinin anemia

          -  Immune hemolytic anemia and/or thrombocytopenia

          -  Nephropathy related to WM

          -  Amyloidosis related to WM

          -  Hemoglobin less or equal than 10g dL

          -  Platelet count less than 100 109 L

          -  Prior treatment for WM comprising at least one regimen containing a therapeutic anti
             CD20 monoclonal antibody rituximab administered for more or equal than 2 doses of
             antibody treatment and or a therapeutic chemotherapy, alkylating agent, purine
             analogue, bendamustine administered for more or equal than 2 cycles of treatment

          -  Patients may be either relapsing progressing at least 6 months after the last
             administration of first line or subsequent treatment or refractory progressing on or
             within 6 months of first line or subsequent treatment

          -  Number of prior regimens per lines 1 to 3

          -  Life expectancy more than 3 months.

          -  ECOG less or equal than 2.

          -  Meet the following pretreatment laboratory criteria at the screening visit conducted
             within 28 days of study enrollment:

               -  ASAT 2.5 times the upper limit of institutional laboratory normal value.

               -  ALAT 2.5 times the upper limit of institutional laboratory normal value.

               -  Total bilirubin 1.5 times the upper limit of institutional laboratory normal
                  value unless clearly related to the disease or Gilbert syndrome

               -  Calculated or measured creatinin clearance by MDRD 40 mL minute.

          -  Premenopausal fertile females must agree to use a highly effective method of birth
             control for the duration of the therapy up to 6 months after end of therapy.

          -  A highly effective method of birth control is defined as those which result in a low
             failure rate when used consistently and correctly such as implants, injectables,
             combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.

          -  Men must agree not to father a child for the duration of therapy and 6 months after
             and must agree to advice a female partner to use a highly effective method of birth
             control.

          -  Voluntary written informed consent before carrying out any study related procedure not
             part of normal medical care, with the understanding that consent may be withdrawn by
             the subject at any time without prejudice to future medical care.

        Exclusion Criteria:

          -  Prior treatment with phosphatidylinositol 3 kinase PI3K inhibitors including
             idelalisib or GA101

          -  History of anaphylactic reaction following exposure to humanized monoclonal antibodies

          -  Previous allogeneic transplantation

          -  Treatment with any other investigational agent or participating in another trial
             within 30 days prior to entering this study

          -  History of other malignancy or chemotherapy radiotherapy for any neoplastic disease
             other than WM prior to the study.

               -  EXCEPTION: History of malignancy except basal cell carcinoma of the skin, in situ
                  carcinoma of breast or cervix treated surgically with curative intent, or any
                  malignancy that has been in CR for 5 years at minimum, or as deemed appropriate
                  for inclusion in the trial as per approval by the investigator

          -  Medical condition requiring the long-term estimated to be more than one month use of
             oral corticosteroids.

          -  Patients with signs of bacterial, viral or fungal infection

          -  Preexisting hepatic enzyme elevation ASAT, ALAT

          -  CMV PCR or antigenemia testing positive

          -  Known history of drug induced liver injury, chronic active hepatitis C HCV, chronic
             active hepatitis B HBV, alcoholic liver disease, non-alcoholic steatohepatitis,
             primary biliary cirrhosis, on-going extra-hepatic obstruction caused by
             cholelithiasis, cirrhosis of the liver or portal hypertension

          -  HIV antibody positive

          -  Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb):
             Patients with presence of HBcAb, but absence of HBsAg, are eligible if hepatitis B
             virus (HBV) DNA is undetectable (&lt; 20 IU). Patients with positive serology should be
             referred to a hepatologist or gastroenterologist before start of treatment and should
             be monitored and managed following local standards to prevent hepatitis reactivation.
             Furthermore transaminases and HBV DNA quantification must be tested at weeks 4 and 8
             after treatment start. Then transaminases must be tested at week 12 of treatment
             start.

          -  Preexisting pulmonary disease

          -  Known history of drug induced pneumonitis

          -  On-going inflammatory bowel disease

          -  Women who are pregnant. Women who are breast-feeding and do not consent to discontinue
             breast-feeding Women of childbearing age who are not willing to use effective
             anti-conceptive methods for the duration of the study and 6 months after end of
             therapy

          -  Concurrent severe diseases which exclude the administration of therapy:

          -  Heart insufficiency NYHA grade III IV, LVEF &lt; 50% and or RF &lt;30%, myocardial
             infarction within the past 6 months prior to study

          -  Severe chronic obstructive lung disease with hypoxemia

          -  Severe diabetes mellitus

          -  Hypertension difficult to control

          -  Cerebral dysfunction

          -  Richter's syndrome

          -  Cardiac amyloidosis

          -  Any of the following laboratory abnormalities, if not related to lymphoma:

          -  Absolute neutrophils count &lt;1.5 x 109/L if not result of a bone marrow infiltration
             Platelet count &lt;75 x 109/L if not result of a bone marrow infiltration.

          -  Central Nervous System involvement by lymphoma

          -  Vaccination with live vaccines within 28 days prior to study entry

          -  Hypersensitivity to the active substance or to any of the excipients listed on part
             6.1 of GAZYVARO and ZYDELIG SmCP

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  No consent for registration, storage and processing of the individual
             disease-characteristics and course as well as information of the family physician
             about study participation

          -  Patient with mental deficiency preventing proper understanding of the requirements of
             treatment

          -  Person major under law control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine NOLLET, Mrs</last_name>
    <role>Study Director</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Véronique LEBLOND, MD PD</last_name>
    <phone>+33142162824</phone>
    <email>veronique.leblond@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cécile TOMOWIAK, MD</last_name>
    <phone>+33549444307</phone>
    <email>cecile.tomowiak@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Project manager</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine NOLLET, Mrs</last_name>
      <phone>+33218370609</phone>
      <email>d.nollet@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie ROY, Mrs</last_name>
      <phone>+33247361896</phone>
      <email>filo@univ-tours.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>E CRF</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

